UBS Group’s Humacyte Inc Warrant HUMAW Stock Holding History

UBS Group’s Portfolio HUMAW Stock Details HUMAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-894	Closed	-$84	–	10798
2025 Q4	$84	Buy	894 +823	+1,159%	+$157	﹤0.01%	10212
2025 Q3	$19	Buy	+71	New	+$24	﹤0.01%	10137
2024 Q3	–	Sell	-7,925	Closed	-$11K	–	9742
2024 Q2	$11K	Buy	+7,925	New	+$9.82K	﹤0.01%	7663
2024 Q1	–	Sell	-5,403	Closed	-$2.25K	–	9630
2023 Q4	$2.25K	Buy	+5,403	New	+$2.65K	﹤0.01%	8141

Other funds holding HUMAW

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

UBS Group's HUMAW Position: Q1 2026 in Review

UBS Group sold out of Humacyte Inc Warrant (HUMAW) in Q1 2026, closing a stake of 894 shares — an estimated $84 sold.

UBS Group first reported a position in HUMAW in Q4 2023 and held it in 4 quarters. The position peaked at $11K in Q2 2024. 7 funds tracked by Wall St. Rank hold HUMAW as of Q1 2026.

UBS Group reported no remaining Humacyte Inc Warrant position as of Q1 2026 after selling out during the quarter.
UBS Group sold 894 Humacyte Inc Warrant shares in Q1 2026, an estimated $84.
UBS Group first reported a position in Humacyte Inc Warrant in Q4 2023 and held it in 4 quarters.
UBS Group's Humacyte Inc Warrant position peaked at $11K in Q2 2024.
7 funds tracked by Wall St. Rank held Humacyte Inc Warrant as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.